Yahoo Web Search

Search results

1. • Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview

     Guru Focus· 4 days ago

     On May 9, 2024, Nektar Therapeutics (NKTR, Financial) disclosed its financial results for the first quarter ended March 31, 2024, through an 8-K filing. The biopharmaceutical company, known ...

2. • 

     Sanofi CSO Frank Nestle is leaving

     FierceBiotech· 6 days ago

     Sanofi Chief Scientific Officer and Head of Research Frank Nestle, M.D., is leaving the company. The news was relayed to staff by R&D chief Houman...

3. • Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

     Zacks· 2 days ago

     Free Report) and partner Regeneron (REGN Quick QuoteREGN - Free Report) announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for the blockbuster ...

4. • 

     1 No-Brainer Growth Stock to Buy and Hold | The Motley Fool

     The Motley Fool· 3 days ago

     All of these superlatives (and more) describe Eli Lilly's (LLY -1.50%) performance in recent years...

5. • 

     Microneedle Magic: New Alopecia Treatment Can Reverse Hair Loss

     SciTechDaily· 6 days ago

     A new microneedle patch effectively treats alopecia areata by rebalancing the immune response...

6. • 

     Here are Friday's biggest analyst calls of the day: Nvidia, Tesla, Apple, 3M, Bumble, Nike, Walmart,...

     CNBC· 4 days ago

     Here are the biggest calls on Wall Street on Friday: Bernstein reiterates Nvidia as outperform...

7. • 

     Earnings Superstars: 3 Stocks Primed to Outperform This Quarter

     InvestorPlace· 6 days ago

     Companies have generally managed to perform well against the consensus of earnings forecasts, with...

8. • vTv Therapeutics (NASDAQ:VTVT) Lowered to Sell at StockNews.com

     ETF DAILY NEWS· 14 hours ago

     StockNews.com cut shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) from a hold rating to a sell rating in a research report report published on Monday. vTv Therapeutics Trading Down 0.3 ...

9. • Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview

     GuruFocus.com via Yahoo Finance· 4 days ago

     The company's lead immunology candidate, REZPEG, is advancing in Phase 2b studies for atopic dermatitis and alopecia areata, with results expected in the ...

10. • AbbVie Inc. (NYSE:ABBV) Receives $174.31 Average Target Price from Brokerages

      ETF DAILY NEWS· 3 days ago

      Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the stock, MarketBeat ...